Objective: Among women with breast cancer, hot flashes are frequent, severe, and bothersome symptoms that can negatively impact quality of life and compromise compliance with life-saving medications (eg, tamoxifen and aromatase inhibitors). Clinicians' abilities to treat hot flashes are limited due to inadequate understanding of physiological mechanisms involved in hot flashes. Using an acute tryptophan depletion paradigm, we tested whether alterations in central serotonin levels were involved in the induction of hot flashes in women with breast cancer.
F or breast cancer survivors, the hot flash is a frequent, severe, bothersome, and persistent problem 1<5 that negatively impacts daily activities, mood, sleep, and overall quality of life. 6 Abrupt withdrawal of hormone therapy at the time of breast cancer diagnosis and treatment with selective estrogen receptor modulators, 7<10 aromatase inhibitors, 11 or chemotherapy 10, 12 can precipitate and/or exacerbate hot flashes. Treating hot flashes in this group is difficult due to contraindications against hormone therapy 13, 14 and limited understanding of hot flash etiology.
Although there is strong evidence implicating reduced serotonin in the etiology of hot flashes, 15, 16 the mechanism underlying serotonin involvement is unclear. Low serotonin has been observed in women after spontaneous or surgical menopause. 17, 18 Estrogen replacement alleviates hot flashes and restores serotonin concentrations. 17, 18 Estradiol also augments serotonergic activity in postmenopausal women. 19 Estrogen seems to affect serotonin metabolism through direct effects on serotonin neurons, which regulate genes involved in serotonin synthesis, transport, and signaling. 20, 21 Patients with carcinoid tumors also experience hot flashes. 22, 23 Although carcinoid tumors are associated with high peripheral serotonin levels, presumably, central serotonin levels are low. 22, 23 Similarly, elevated peripheral serotonin concentrations in perimenopausal women that were positively correlated with hot flashes likely reflect low central levels of serotonin. 24 Based on these and other data, selective serotonin reuptake inhibitors (SSRIs) or selective norepinephrine reuptake inhibitors (SNRIs) are frequently used to treat hot flashes. 25, 26 One method for evaluating the role of central serotonin in hot flashes is the acute tryptophan depletion paradigm. This paradigm has been widely used and accepted within the field of psychiatry to evaluate the role of central serotonin neurotransmission in various disorders such as depression, panic disorder, and premenstrual syndrome. 27<30 It can be used without serious medical or psychological complications even in women with such disorders. 28,30<33 This paradigm alters serotonin function in humans, as confirmed with cerebrospinal fluid sampling, 34 without the side effects associated with pharmacological agents. In addition, effects are specific for serotonin. There are no direct effects on other neurotransmitters. 32 Tryptophan is the precursor for serotonin synthesis and is a naturally occurring amino acid found in foods such as turkey, cheese, and nuts. Because tryptophan is transported into the brain and can be rate limiting for serotonin synthesis, decreasing circulating tryptophan causes a temporary suppression of central serotonin synthesis and concentrations. Acute tryptophan depletion is accomplished by administering a 80-to 100-g amino acid drink that contains no tryptophan. Central tryptophan becomes temporarily depleted as (1) hepatic protein synthesis uses up the existing tryptophan and (2) tryptophan competes at a relative disadvantage with the other large neutral amino acids supplied in the drink for the amino acid transporters that transport tryptophan into the brain. 31, 32 Acute tryptophan depletion results in temporary lowering of central serotonin neurotransmission within 5 to 7 hours. 28, 32 Adverse effects (nausea, mood changes) are mild and subside after ingestion of a tryptophan-containing meal.
The purpose of this study was to directly reduce central serotonin via acute tryptophan depletion and study acute effects on hot flashes in breast cancer survivors. Our main hypothesis was that deficits in central serotonin levels were involved in the induction of hot flashes in these women who are at heightened vulnerability to hot flashes due to their cancer treatments. Because genetic variations in serotonin receptor and transporter genes have been documented, 35<38 we also hypothesized that variability in response to serotonin manipulation could be partly explained by genetic variations.
METHODS

Sample and setting
Participants were recruited from a Midwestern outpatient cancer clinic from 2005 to 2007. All procedures were approved by a local institutional review board, a cancer center scientific review committee, and the funding agency human subjects review board. All participants were (1) adults at least 18 years of age (actual age range, 30-71 y); (2) willing and able to provide informed consent; (3) reporting daily hot flashes; (4 ) able to read, write, and speak English; (5) postmenopausal (Q12-mo amenorrhea 39, 40 ); and (6) greater than 1 month but less than 5 years posttreatment (surgery, radiation, chemotherapy) for nonmetastatic breast cancer. These criteria allowed inclusion of women successfully treated for recurrent breast cancer because there was no known reason to exclude them. 10 Exclusion criteria were as follows: (1) current depression, (2) history of migraines, (3) history of hepatitis, and (4 ) abnormal chemistry profile (eg, sodium, potassium, and glucose). Women taking SSRIs/SNRIs were not excluded for two reasons: (1) acute tryptophan depletion was expected to produce a relapse of hot flash symptoms in SSRI/SNRI users, 31, 32 and (2) we did not want to bias the sample toward those who may not be taking SSRIs/SNRIs for hot flashes due to lack of efficacy.
Design and intervention
The study was a within-participant, double-blind, controlled, balanced, crossover trial. Participants took part in two 9-hour clinic visits 7 days apart. They received in random order either acute tryptophan depletion drink and capsules or a one-quarter strength control drink and capsules.
Acute tryptophan depletion was achieved with a 300-mL amino acid drink and encapsulated amino acids containing 100 g total amino acids in the following ratio: L-alanine (5.5 g), L-arginine (4.9 g), L-cysteine (2.7 g), glycine (3.2 g), L-histidine (3.2 g), L-isoleucine (8.0 g), L-leucine (13.5 g), L<lysine (11.0 g), L-methionine (3.0 g), L-phenylalanine (5.7 g), L-proline (12.2 g), L-serine (6.9 g), L-threonine (6.9 g), L-tyrosine (6.9 g), and L-valine (8.9 g). 41<43 Orange or chocolate mint flavoring was used to improve palatability of the drink. Cysteine, methionine, and arginine were encapsulated due to their unpleasant taste. 34, 41, 43 We used a 100-g drink rather than the 80-g drink used in some studies to produce the greatest effect. The 100-g drink was expected to produce acute tryptophan depletion within 4.5 to 7 hours, with a 80% to 90% drop in plasma tryptophan 31, 33, 34 and concomitant drop in central tryptophan. 34 The control arm was a 300-mL drink and encapsulated amino acids but in one-fourth strength: L-alanine (1.4 g), Larginine (1.2 g), L-cysteine (0.7 g), glycine (0.8 g), L-histidine (0.8 g), L-isoleucine (2.0 g), L-leucine (3.4 g), L-lysine (2.8 g), L-methionine (0.8 g), L-phenylalanine (1.4 g), L-proline (3.1 g), L-serine (1.7 g), L-threonine (1.7 g), L-tyrosine (1.7 g), L-valine (2.2 g), and fillers (7.95 g). 32, 44 The control drink was expected to lower tryptophan only 25%. Other studies have used tryptophan supplementation as a control condition; however, this practice has been criticized because changes in tryptophan and serotonin can be highly variable. 32 We did not compare depletion to both the control and supplementation because this would have required participants to take part in three all-day study visits.
Randomization and blinding
Biostatisticians created a computer-generated randomization sequence, with randomization done in blocks of four without stratification. After informed consent was obtained, the participant's study number was sent to the study dietitian who randomized the participant to one of two sequence groups: acute tryptophan depletion/control or control/acute tryptophan depletion. The study dietitian carried out the randomization using amino acids supplied by the investigative team. The dietitian dispensed depletion and control drinks in metal cups with black opaque lids and straws to prevent participants, nurses, or study staff from seeing the drink contents. The project manager checked each drink outside the participant's room to ensure that the dietitian had carried out the randomization appropriately. Thus, the dietitian and the project manager were not blinded. Participants and specified team members (nurses, data collectors, hot flash analysts, data entry personnel, laboratory technicians) were blinded. In the consent form, participants were told that they would receive two different amino acid drinks in random order. The notion of an active drink and a control or placebo drink was never introduced to them. Thus, participants were not aware that an active drink was being compared with a control drink, and participants who noticed a difference in the viscosity of the drinks were not able to link the more viscous drink to the active condition. In addition, the number of capsules for the unpleasant tasting amino acids was identical between arms.
Study procedures
Women were recruited in the cancer clinic or by telephone after being referred to the study by clinic staff. They were told about the study, were screened for eligibility, and, if eligible and interested, were mailed a packet of study materials and asked to return signed consent forms in prepaid envelopes. After consenting, women were interviewed by the study psychologist who verified their eligibility as nondepressed using the Hamilton Rating Scale-Depression. Women were then scheduled for their first study visit.
Procedures for the two study weeks were identical. Participants arrived at the General Clinical Research Center after fasting for 8 hours. Outpatient admission procedures included the following: obtaining a brief medical history, physical examination, vital signs, height, and weight; collecting a urine sample for drug screening; placing an intravenous catheter with heparinized saline for blood draws; and starting objective hot flash monitoring. To obtain a baseline, blood was drawn and the participant was asked to fill out demographic, symptom, and mood questionnaires. The study start (time 0) coincided with ingestion of the amino acids. Subsequent blood draws were completed hourly for 8 hours. Symptom and mood questionnaires were completed 3, 5, and 7 hours later. Participants engaged in quiet activities while being monitored by nurses. Eight hours later, a meal containing 0.25 g of tryptophan was served (the amount of tryptophan in 3 oz of cooked turkey breast). The study psychologist verified absence of depressive symptoms, the intravenous access was removed, and women were discharged wearing a hot flash monitor. The next morning, a trained nurse telephoned participants with instructions for turning off and disconnecting the hot flash monitor. The nurse verified the absence of depression using the Hamilton Rating Scale-Depression (she was trained by the study psychologist to do this), assessed side effects using a checklist, and reminded participants to bring the hot flash monitor with them to their week 2 visit. Week 2 was completed 7 days later. The week 2 monitor was returned by mail.
Measures
Demographic information was collected with a questionnaire (birthdates, race, marital status, education, employment status, income, current medications, menopause status, gyne-cological and reproductive history). 6, 45, 46 Breast cancer information was self-reported by participants and verified through medical record review (date of diagnosis, disease stage, and dates/types of treatments). In addition, participants were asked to complete the Co-morbidity Questionnaire to document the presence of medical problems, if the condition caused problems, required medication, and/or limited activities. 47 Safety monitoring was completed as follows. First, the Hamilton Rating Scale-Depression 48,49 was used to rule out depressive symptoms at study entry, at the end of each test day, and the day after each test day (eg, score e18). This scale has been used to monitor response and/or safety in other acute tryptophan depletion studies. 27 Interrater reliability between the study psychologist and study nurse exceeded 90%. Second, mood and physical side effects were monitored throughout each test day (baseline and hours 3, 5, 7) and the next morning. The Profile of Mood States-Short Form is a 37-item scale that is based on the 65-item version. 50, 51 This list of adjectives is rated on a 0 to 4 point scale, and responses are summed to generate a total score and six subscale scores (depression, tension, anger, confusion, vigor, fatigue). This scale has been used in other studies to monitor response to acute tryptophan depletion. 27 Reliability and validity in women with breast cancer have been supported. 52 The Side Effects Report consisted of a list of 24 physical symptoms, including symptoms previously associated with acute tryptophan depletion (nausea, vomiting, nervousness, loss of concentration). 53, 54 Respondents indicated if they were having each symptom (no, yes) and, if so, rated severity using a 0 (not at all)-to 4-point (extremely) scale. Third, serum glucose was assessed at each hourly blood draw (YSI Life Sciences Instrument, Yellow Springs, OH). Glucose tablets were administered by mouth for glucose values 70 mg/dL or less. All safety monitoring data were reviewed routinely by the investigative team and a data safety monitoring board.
Hot flash response was monitored as follows. Physiological hot flash frequency was assessed using sternal skin conductance monitoring. 45, 46 ,55<57 Participants wore the monitor during the test day and during the nighttime at home for a total of 24 hours. At the end of the monitoring session, the monitor was downloaded and scored using customized software and established procedures. 45, 46 ,55<57 Scoring was done by trained raters, with interrater reliability exceeding 90%. Sternal skin conductance monitoring is the gold standard measure of physiological or objective hot flash frequency only. 46, 58 Each hot flash is defined as an increase of 2 units within a 30-second period. Skin conductance magnitude was the sum total change in skin conductance with each physiological or self-reported hot flash. Self-reported hot flash frequency, severity, and bother were assessed using written diaries and electronic event markers during the 24-hour period. When the participants experienced a hot flash, they were instructed to push the two red buttons on the hot flash monitor, write down the time of the hot flash, and rate severity and bother in a paper diary (0 = not at all and 10 = extremely severe or 10 = extremely bothersome). (2) assessment of tryptophan/large neutral amino acid (TRP/LNAA) ratios at the presumed 5-hour tryptophan nadir each week. Whole blood tryptophan, hydroxyltryptophan, serotonin, and kynurenine were assayed with high-performance liquid chromatography (HPLC) using procedures similar to that described by others. 59 The large neutral amino acids concentrations were determined by the Waters Pico-Tag methods. Briefly, the amino acids were derivatized with phenylisothiocyanate forming phenylthisocarbamyl derivatives. The resulting samples were then analyzed by reversed-phase HPLC separation and ultraviolet detections, using a Waters Alliance HPLC system.
Genetic polymorphisms in three serotonin-related candidate genes were assessed for association with the hot flash response. We chose these specific polymorphisms because previous publications have reported that they were associated with clinical phenotypes. The following single nucleotide polymorphisms (SNPs) were genotyped: rs6313 and rs799701 in the serotonin receptor 2A gene (HTR2A); rs1800532 from the tryptophan hydroxylase gene (TPH1); and rs6295 from the serotonin receptor 1A (HTR1A) gene. DNA was extracted from whole blood using the Gentra DNA extraction kit. The HTR1A and HTR2A SNPs were genotyped using TaqMan assays from Applied Biosystems, Inc (assay identification nos. c__11904666_10 [rs6295], c__3042197_1 [rs6313], and c__1619749_10 (rs7997012)).
Genotyping for the TPH1 SNP was conducted using an allelespecific polymerase chain reaction assay as follows: we used the iCycler system (Bio-Rad) with allele-specific primers (common forward primer: 5 ¶-AGA ATG GTA CCT GGC ATG AAA-3 ¶, reverse primer for the allele containing A: 5 ¶-C CTA TGC TCA GAA TAG CAG CTC T-3 ¶, reverse primer for the allele containing C: 5 ¶-CTA TGC TCA GAA TAG CAG CTC G-3 ¶) and with SYBR Green Supermix (Bio-Rad). The allele-specific real-time polymerase chain reaction was running for 45 cycles at 95-C for 10 seconds and 55-C for 45 seconds. Alleles were discriminated based on their Ct values.
Statistical analysis
A preliminary analysis of the first four participants indicated that 25 participants were needed to provide 80% power to detect a modest and significant difference between depletion and control arms using a paired t test and > of 0.05.
The following analyses were done to verify experimental procedures. Sample characteristics were examined using descriptive statistics. Two-sided t tests and Fisher's exact tests were used to compare characteristics of participants who received depletion/control and control/depletion. To verify that adequate depletion was reached, we used (1) repeatedmeasures analysis to compare the percent change in serum tryptophan over time between randomized groups and (2) Fisher's exact tests to compare tryptophan values and TRP/ LNAA ratios at the nadir time point (5 h after drink ingestion) between groups. After examining correlations among hot flash measures using Pearson's correlations, the main hypothesis was tested using two sets of hot flash variables: (1) those based on data from the total 8-hour test day (from drink ingestion to 8 h later [hours 0-8]) and (2) those based on a 3-hour tryptophan nadir period (from 5 h after drink ingestion to 3 h later [hours [5] [6] [7] [8] ). We tested both week 1 to week 2 carryover effects and week effects using a mixed linear model. Because neither of the effects were significant, we were able to ignore the order effect and collapse data for paired t tests comparing depletion to control using all participants as their own controls. Because five participants vomited at some point during the acute tryptophan depletion clinic day and that could potentially confound effects of the tryptophan depletion, we also compared hot flashes between those who achieved the greatest depletion compared with those with a less effective depletion based on (1) tryptophan concentrations less than 10 KM at hour 5 versus 10 KM or more at hour 5 and (2) TRP/LNAA less than 0.007 versus 0.007 or more. These cutoffs were determined empirically based on visual inspection of the data. For both measurements, the values appeared in one of two groups that were separated by a region of concentrations in which no samples were observed. We also tested whether the response to the acute tryptophan depletion versus control conditions varied by the following: use of SSRIs/SNRIs, antiestrogens (such as tamoxifen or aromatase inhibitors), breast cancer disease and treatment variables (time since diagnosis, type of treatment), and genetics. Because of the small sample sizes, genetic analyses were conducted by descriptive methods.
RESULTS
The accrual flow is shown in Fig. 1 . Of the 36 consenting women, 5 expressed lack of interest and withdrew and 3 were withdrawn due to ineligibility. Of the remaining 28 women, 28 completed week 1 and 27 completed week 2 (1 withdrew after week 1 due to dizziness occurring 3 d after the study visit). Genetic analyses were available for all women. However, beacuse of difficulties in sustaining venous access, only 24 women had serial tryptophan and metabolites data during the depletion week and only 23 during the control week.
The 27 participants were mostly white (93%), were married or living with a partner (82%), and had household incomes more than $60,000 (59%). Mean (SD) age was 53.4 (9.6) years (range, 30-71 y). All had been successfully treated for nonmetastatic breast cancer (eg, stage III or less) and were considered to be free of cancer at the time of the study. Mean (SD) time after completion of primary treatment (eg, surgery, chemotherapy, and radiation) was 37.8 (18.6) months (range, 13-77 mo). Breast cancer treatments received included surgery alone (15%), surgery with radiation therapy (15%), surgery with chemotherapy (19%), and surgery with radiation and chemotherapy (52%). No participants were taking hormone therapy, 37% were taking tamoxifen, 42% were taking an aromatase inhibitor, and 33% were taking an SSRI/SNRI. Hours 0 to 7 were during the test day for each condition. Total mood disturbance scores were not significantly different over time (P 9 0.20). C' Number and mean severity of side effects over time for each condition. Participants (n = 27) indicated if they were having symptoms using a checklist and if the number they endorsed was summed to calculate the total number of symptoms. For each symptom that they endorsed, participants rated severity from 0 (not at all) to 4 (extremely). Mean severity for all symptoms endorsed was calculated (total severity/ total number of symptoms). The closed triangle and circle refer to the active amino acid drink and the open triangle and circle to the control drink. Hours 0 to 7 were during the test day for each condition. Number and severity of symptoms were not significantly different between study arms over time (P 9 0.20). No significant differences were found between those randomized to depletion/control versus control/depletion for age, race, marital status, education, employment, income, or SSRI/SNRI use (P 9 0.10).
Adverse events included the following. During acute tryptophan depletion, five participants vomited. Vomiting occurred within 20 minutes after ingesting amino acids (n = 1) or between 4 and 6.25 hours later (n = 4). One woman experienced hypoglycemia 3 hours after drink ingestion during both study visits that was resolved with glucose tablets. Mood was not significantly impacted. Hamilton Rating Scale-Depression scores remained less than 18 at all time points and for both study arms. Similarly, total mood disturbance and symptom rating scores were not significantly different between study arms over time (P 9 0.20; see Fig. 2 ).
The percent change in serum tryptophan during depletion and control conditions is shown in Fig. 3 . Baseline, 1-hour, and 2-hour total tryptophan values were not significantly different (P = 0.46) between the group randomized to depletion treatment first and the group randomized to depletion second. However, the tryptophan depletion group had significantly lower total tryptophan than the control group at hours 3 through 8, indicating that adequate separation between study arms was achieved. As expected, during the nadir period (5 h after drink ingestion), 83% of women receiving tryptophan depletion had total tryptophan values less than 10 KM compared with 35% in control group (P = 0.001). Similarly, nadir TRP/LNAA ratios were significantly lower at hour 5 during tryptophan depletion (mean [SD], 0.0034 [0.0027]) compared with control (mean [SD], 0.02 [0.02]) (P e 0.0001).
As shown in Table 1 , objective hot flash frequency and magnitude were highly correlated. Similarly, subjective hot flash variables (diary frequency, event button frequency, in-tensity, bother) were highly correlated. Correlations between objective and subjective hot flash variables were modest (0.46 G r G 0.58) in this study but higher than correlations for similar data collected during ambulatory monitoring outside a laboratory (0.06 G r G 0.26). 60 Table 2 shows no significant differences in any hot flash variables between depletion and control conditions for any of the 8-hour long variables or any of the 3-hour long tryptophan nadir variables. Not shown are t tests for differences between groups based on tryptophan response and TRP/ LNAA response. These t tests were similar and nonsignificant. In addition, response did not vary by use of SSRIs/ SNRIs, antiestrogens, breast cancer disease and treatment variables, or genetic variants in the HTR1A, HTR2A, and TRH1 genes.
DISCUSSION
The primary aim of this study was to investigate the effects of lowered serotonin synthesis by acute tryptophan depletion on hot flashes in female survivors of breast cancerVa group known to have frequent, severe, and bothersome hot flashes. It was hypothesized that acute tryptophan depletion would exacerbate hot flashes; however, our data did not support this assumption. We did not find any significant differences between study conditions for objective or subjective hot flash measures.
There are two potential explanations for these negative study findings. First, if central serotonin functioning was severely diminished in these postmenopausal women, we may not have accomplished a further reduction in serotonin with acute tryptophan depletion. Although women are generally more susceptible than men to the effects of acute tryptophan depletion on memory, 61 estrogen loss at menopause may affect how postmenopausal women respond to acute tryptophan depletion. Loss of estrogen seems to diminish serotonin concentrations, activity, and metabolism 17<21 Thus, we may not have accomplished further Repeated-measures analysis indicated that tryptophan values were not significantly different (P = 0.46) between randomized groups at hours 0, 1, or 2 but were significantly lower in the acute tryptophan depletion group compared with control group at hour 3 (P G 0.01) and hours 4, 5, 6, 7, and 8 (P G 0.001). Significant differences are shown with an asterisk next to the time point (ie, hours 3 through 8). If central serotonin levels are already low in these women, an alternative approach is to provide additional tryptophan by dietary supplementation. However, this assumes a substrate limitation rather than an enzyme limitation. If menopause alters the enzymes involved in converting tryptophan to serotonin, adding more substrate would not produce a response. However, there is evidence suggesting that tryptophan supplementation may have merit. For example, tryptophan supplements have been suggested as a potential hot flash treatment 62 and seem to impact other symptoms. For example, in women, tryptophan significantly reduced premenstrual dysphoric symptoms compared with placebo. 63, 64 In humans, primates, and rats, tryptophan decreases mild depressive symptoms and aggressive behavior. 65, 66 Chronic tryptophan supplementation raises plasma tryptophan and central serotonin and potentiates SSRI effectiveness in rats. 67, 68 Although contaminated tryptophan supplements were thought to cause eospinophilia myalgia syndrome, 69 today, dietary manipulation of tryptophan or L-tryptophan/ 5-hydroxytryptophan supplementation is considered to be a safe intervention. 65, 66, 68, 70 A second explanation for negative study findings may be that acute tryptophan depletion alone, without an additional stressor such as a thermal challenge, may not have been adequate to invoke hot flashes. A similar paradigm has been seen in panic and obsessive-compulsive disorders. Tryptophan depletion alone does not provoke panic; however, it increases susceptibility to panic so that if a stressor is applied during tryptophan depletion (ie, flumazenil), panic symptoms are exacerbated. 28 Similarly, symptoms of obsessive-compulsive disorder emerge after acute tryptophan depletion only when an additional stressor is present. 71 In this study, tryptophan depletion may have increased susceptibility to hot flashes, but normal environmental stressors were controlled due to the laboratory setting (eg, absence of temperature and humidity fluctuations, absence of emotional stressors). This hypothesis could be tested in a follow-up study by comparing time to hot flash onset or hot flash frequency, intensity, or bother after a stressor such as application of heating pads during acute tryptophan depletion and control conditions. Study findings should be considered in light of study limitations. Although the sample size was comparable or larger than that seen in more than 70 similar studies included in a recent review, 27 the sample was limited in terms of ethnic and racial diversity, yet heterogeneous in relation to breast cancer disease and treatment characteristics. In addition, this sample of breast cancer survivors does not provide any indication of how healthy postmenopausal women who have not undergone breast cancer treatment would respond. Finally, the design was limited in that it did not include a study arm to evaluate the effects of tryptophan or 5hydroxytryptophan supplementation. Some previous studies have used tryptophan supplementation for comparison. 28 However, because of reported variable increases in tryptophan and serotonin with supplementation 32 and anticipated difficulties in recruiting women to take part in an additional study visit, we chose to use a one-quarter strength drink as the control condition. This control condition reduced plasma tryptophan levels more than the 25% that was expected, and the reasons for this are unknown. However, the control drink did differ from the full strength depletion in that depletion occurred to a lesser degree and with faster recovery. 32 
CONCLUSIONS
In summary, to our knowledge, this was the first study to examine hot flash physiology using acute tryptophan depletion. Further testing of our study hypothesis may be warranted through tryptophan supplementation or a tryptophan depletion with stressor paradigm. Findings indicate that additional research on mechanistic pathways is needed to guide appropriate treatment in clinical practice. Three-hour period spanning 5 to 8 hours after drink ingestion. c Sum of all changes in skin conductance that accompanied objective and subjective hot flashes.
